Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma
Conditions
Malignant Pleural Mesothelioma
Conditions: official terms
Mesothelioma
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Overall Status
Recruiting
Summary
To Study the Effect of Polymorphisms in Fas Ligand Gene Promoter Region (rs 763110) and Fas gene (rs1800682) on Platinum-Based regimens used in treatment of malignant pleural mesothelioma (MPM)
Detailed Description
This study tries to find a correlation between single nucleotide polymorphisms (SNP) found in promoter region of Fas Ligand gene (rs 763110) and Fas (rs1800682) and clinical outcome on patients with MPM treated with platinum-Based agents as first line. the patients will have one of three following genotypes : Thymine/Thymine, Thymine/Cytosine or Cytosine/Cytosine (for Fas ligand polymorphism) and Adenine/Adenine, Adenine/Guanine or Guanine/Guanine ( for Fas polymorphism).
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients with histologically confirmed Malignant Pleural Mesothelioma

- Age of 18 years or more.

- first-line chemotherapy with platinum-Based agents

Exclusion Criteria:

- history of prior malignancy.

- pregnancy or lactation or any other reason preventing him from taking platinum-Based chemotherapy (AST more than 2.5* Upper Limit of Normal or Serum bilirubin more than 1.5* Upper Limit of Normal)
Location
Ain Shams University Hospitals
Cairo, Abbasia, Egypt
Status: Recruiting
Contact: Ahmed mohammed Abdoe Mohammed Salem, B.PHARM - 0020226838052 - mabdo3@hotmail.com
Start Date
October 2014
Completion Date
October 2016
Sponsors
Ain Shams University
Source
Ain Shams University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page